IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of human IGF-1, an 83-amino acid analog compared to the 70-amino acid native IGF-1. The modifications include substitution of glutamic acid at position 3 with arginine (R3) and addition of a 13-amino acid N-terminal extension peptide. These modifications dramatically reduce binding to IGF-binding proteins (IGFBPs), resulting in enhanced bioavailability and a 2-3 fold longer half-life than native IGF-1. Native IGF-1 circulates primarily bound to IGFBPs (especially IGFBP-3), which regulate its activity and limit tissue exposure. By evading IGFBP binding, IGF-1 LR3 remains in its free, biologically active form for extended periods, producing significantly more potent anabolic and metabolic effects than equivalent doses of native IGF-1. IGF-1 is the primary mediator of growth hormone's anabolic effects and is critical for muscle growth, fat metabolism, bone development, and tissue repair. IGF-1 LR3 was originally developed as a research tool for IGF-1 biology and is used in cell culture media to enhance cell proliferation. Its potent anabolic properties have attracted interest in muscle building, recovery, and age-related decline research.

IGF-1 Receptor Activation IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase heterotetrameric receptor (α2β2). Ligand binding activates the intrinsic tyrosine kinase of the β-subunits, triggering autophosphorylation and recruitment of insulin receptor substrate (IRS) proteins. This initiates two major downstream signaling cascades: PI3K/Akt/mTOR (metabolic/survival) and Ras/MAPK (proliferative). Enhanced Bioavailability The key pharmacological advantage of IGF-1 LR3 over native IGF-1 is its greatly reduced binding to the six IGF-binding proteins (IGFBPs 1-6). Normally, >99% of circulating IGF-1 is bound to IGFBPs, which limit its bioactivity. IGF-1 LR3 circulates predominantly in free form, providing 2-3 times the potency of native IGF-1 at the receptor level. mTOR-Mediated Protein Synthesis Through the PI3K/Akt/mTOR pathway, IGF-1 LR3 activates the mechanistic target of rapamycin (mTOR), which phosphorylates p70S6K and 4E-BP1. This dramatically enhances ribosomal protein synthesis, driving muscle protein accretion and cell growth. mTOR activation is the primary mechanism of IGF-1 LR3's anabolic effects. Satellite Cell Activation IGF-1 LR3 activates skeletal muscle satellite cells (muscle stem cells), promoting their proliferation, differentiation, and fusion with existing myofibers. This hyperplastic growth mechanism (increasing the number of myonuclei) distinguishes IGF-1 from other anabolic agents that primarily produce hypertrophic growth. Anti-Apoptotic Signaling Akt activation by IGF-1 LR3 phosphorylates and inactivates pro-apoptotic proteins (Bad, caspase-9, FKHR), promoting cell survival. This anti-apoptotic effect contributes to tissue protection and regeneration.

Muscle Growth and Hypertrophy IGF-1 LR3 is the most extensively researched IGF-1 analog for skeletal muscle growth. It promotes both hypertrophy (increased cell size through protein synthesis) and hyperplasia (increased myonuclei through satellite cell activation). Research demonstrates dose-dependent increases in lean body mass and muscle cross-sectional area. Cell Culture and Biotechnology IGF-1 LR3 is widely used as a cell culture supplement, replacing serum in media for mammalian cell growth. Its reduced IGFBP binding makes it more effective than native IGF-1 for supporting cell proliferation in vitro. This is its primary commercial application. Muscle Wasting and Sarcopenia Research in age-related sarcopenia and disease-related muscle wasting demonstrates IGF-1 LR3 can counteract muscle atrophy through mTOR-mediated protein synthesis and satellite cell activation. Injury Recovery IGF-1 signaling promotes tissue repair in muscle, tendon, and ligament injuries through enhanced protein synthesis, cell proliferation, and extracellular matrix production. Bone Growth and Density IGF-1 is essential for bone development and maintenance. Research with IGF-1 LR3 demonstrates enhanced osteoblast proliferation and bone formation, with potential applications in osteoporosis and fracture healing. Metabolic Research IGF-1 LR3 is used to study insulin-like metabolic signaling, glucose uptake, and the interplay between growth factor and metabolic pathways in health and disease.

PI3K/Akt/mTOR Anabolic Pathway IGF-1R→IRS-1→PI3K→Akt→mTORC1→p70S6K/4E-BP1: The master anabolic cascade. mTORC1 activation simultaneously enhances protein synthesis (through ribosomal S6 kinase and eIF4E) and suppresses protein degradation (through inhibition of autophagy/FOXO transcription factors). Ras/Raf/MEK/ERK Proliferation Pathway IGF-1R→Shc→Grb2→SOS→Ras→Raf→MEK→ERK1/2: Drives cell proliferation, differentiation, and gene expression. ERK activation is critical for satellite cell proliferation and the mitogenic effects of IGF-1 signaling. FOXO Protein Degradation Inhibition Akt phosphorylates FOXO transcription factors (FOXO1, FOXO3), excluding them from the nucleus and preventing transcription of atrophy-related genes (MuRF1, atrogin-1/MAFbx). This anti-catabolic mechanism reduces muscle protein breakdown. GSK-3β/Glycogen Synthesis Akt phosphorylates and inactivates GSK-3β, relieving inhibition of glycogen synthase. This promotes glycogen storage in muscle and liver, contributing to the metabolic effects of IGF-1 signaling.

Hypoglycemia (Most Significant Risk) IGF-1 LR3 activates the insulin receptor at high concentrations and enhances glucose uptake through IGF-1R/Akt/GLUT4 signaling. This can cause significant hypoglycemia, particularly when combined with insulin or during fasting. Symptoms include shakiness, sweating, confusion, and in severe cases, loss of consciousness. Organ Growth (Organomegaly) Chronic IGF-1 LR3 use at high doses can promote organ enlargement, including intestinal hypertrophy, splenic enlargement, and cardiac hypertrophy. These effects are dose-dependent and more concerning with prolonged use. Joint Pain GH/IGF-1-mediated effects on connective tissue can cause arthralgia. Combined with tissue growth effects, joint pain is commonly reported. Water Retention IGF-1 promotes renal sodium retention, causing fluid accumulation in extremities and face. Tumor Growth Concern IGF-1 signaling promotes cell proliferation and inhibits apoptosis — the same pathways exploited by cancer cells. Elevated IGF-1 levels are epidemiologically associated with increased cancer risk (breast, prostate, colon). Use in individuals with known or suspected malignancies is contraindicated. Jaw and Hand Growth Prolonged exposure to high IGF-1 levels can cause acromegalic features — particularly growth of jaw, hands, and feet due to periosteal bone growth and soft tissue expansion. Insulin Resistance (Paradoxical) While IGF-1 acutely enhances insulin sensitivity, chronic high-dose IGF-1 LR3 can paradoxically impair insulin signaling through IGF-1R/IR cross-desensitization and IRS-1 serine phosphorylation.

IGF-1 LR3 is supplied as a lyophilized white powder and is relatively sensitive to degradation compared to smaller peptides. Store at -20°C or below for long-term stability (12-18 months). At 2-8°C, stability is limited to 1-3 months for lyophilized form. Reconstitute with 0.1M acetic acid or sterile water containing 0.1% BSA (bovine serum albumin) for maximum stability. Avoid bacteriostatic water for reconstitution as the benzyl alcohol can cause protein aggregation. Use gentle swirling — never vortex or shake, as this causes protein denaturation. Once reconstituted, store at 2-8°C and use within 14-21 days. IGF-1 LR3 is susceptible to proteolytic degradation, oxidation (multiple methionine residues), and adsorption to container surfaces. Adding carrier protein (BSA 0.1%) reduces surface adsorption losses. Avoid repeated freeze-thaw cycles.

IGF-1 LR3 is not approved by the FDA or any regulatory authority for human therapeutic use. Native IGF-1 (mecasermin/Increlex) is FDA-approved for severe primary IGF-1 deficiency in children, but IGF-1 LR3 is a distinct compound with different pharmacokinetics. IGF-1 LR3 is classified as a research reagent and cell culture supplement. It is widely available from biotechnology suppliers for laboratory research and cell culture applications. WADA strictly prohibits IGF-1 and all its analogs (including IGF-1 LR3) under category S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). It is banned both in-competition and out-of-competition.